Table of Content


1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Healthcare Expenditure
4.2.2 Growing Adoption of Biosimulation Software
4.2.3 High Drug Discovery and Development Costs
4.3 Market Restraints
4.3.1 Lack of Awareness Among Healthcare Professionals
4.3.2 Lack of Skilled Personnel
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Software
5.1.2 Services
5.2 By Application
5.2.1 Preclinical and Clinical Drug Development
5.2.2 Drug Discovery
5.2.3 Others
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Contract Research Organizations
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Biovia
6.1.2 Certara, L.P.
6.1.3 Compugen Inc.
6.1.4 Genedata
6.1.5 In Silico Biosciences, Inc.
6.1.6 Leadscope Inc
6.1.7 Pharmaceutical Product Development, LLC
6.1.8 Schrodinger, LLC
6.1.9 Simulations Plus, Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS